Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 15/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23810327 | 0.92 | ENPP2 (0.46) | ENPP2ELANEMAT2A | |
| SCHEMBL671766 | 0.92 | ENPP2 (0.67) | ENPP2 | |
| SCHEMBL16751041 | 0.92 | ENPP2 (0.57) | ENPP2ELANEMAT2A | |
| SCHEMBL30147064 | 0.91 | ENPP2 (0.65) | ENPP2MAT2A | |
| SCHEMBL16739426 | 0.91 | ENPP2 (0.65) | ENPP2MAT2A | |
| SCHEMBL16739530 | 0.89 | ENPP2 (0.54) | ENPP2ELANEMAT2A | |
| SCHEMBL16739519 | 0.88 | ENPP2 (0.55) | ENPP2 | |
| SCHEMBL671504 | 0.88 | ENPP2 (0.65) | ENPP2 | |
| SCHEMBL670638 | 0.85 | ENPP2 (0.66) | ENPP2 | |
| SCHEMBL16739475 | 0.85 | ENPP2 (0.57) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268668-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240189281-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | SABRE THERAPEUTICS LLC (US) | 2024-06-13 | — | — | US | disclosed |
| US-11779568-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779568-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779568-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2023-10-10 | — | — | US | disclosed |
| CN-110372671-B | Autotaxin inhibitor compounds | 赛博治疗有限责任公司 | 2023-02-21 | — | — | CN | disclosed |
| US-20220265608-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2022-08-25 | — | — | US | disclosed |
| US-11344533-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2022-05-31 | — | — | US | disclosed |
| US-11344533-B2 | Autotaxin inhibitor compounds | SABRE THERAPEUTICS LLC (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3878848-A1 | AUTOTAXIN INHIBITING INDOLE COMPOUNDS | Sabre Therapeutics LLC (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20160235713-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-08-18 | — | — | US | disclosed |
| US-20160235713-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-08-18 | — | — | US | disclosed |
| US-9334261-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334261-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334261-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160046614-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-02-18 | — | — | US | disclosed |
| US-20160046614-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-02-18 | — | — | US | disclosed |
| US-20160046614-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-02-18 | — | — | US | disclosed |
| WO-2015077503-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077503-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779568-B2 | Autotaxin inhibitor compounds | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885ALOX5 1861/4885ELANE 61/4885 |
| US-20160046614-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885ALOX5 1861/4885ELANE 61/4885 |
| US-20240189281-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885ALOX5 1861/4885ELANE 61/4885 |
| US-11344533-B2 | Autotaxin inhibitor compounds | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885ALOX5 1861/4885ELANE 61/4885 |
| US-20220265608-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885ALOX5 1861/4885ELANE 61/4885 |
| US-20160235713-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885ALOX5 1861/4885ELANE 61/4885 |
| US-12268668-B2 | Autotaxin inhibitor compounds | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885ALOX5 1861/4885ELANE 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.